Inthera Bioscience
Inthera Bioscience AG is a Swiss biotech company. Its lead compound, INTH-454, is an IND-ready oral small molecule drug binding to the Negative Elongation Factor complex of transcription (NELF). Through this binding, INTH-454 interferes with cellular checkpoints of transcription leading in turn to replicative stress induction and DNA synthesis inhibition. INTH-454 induces highly specific killing of tumor cells while leaving normal cells unharmed.
Date, time and room information
May 6, 13:00 - 13:15, room Singapore
Category
Emerging biotech company
Title of the presentation
INTH-454: a First-in-class IND-ready oral small molecule inhibitor of NELFCD, inducing highly specific cancer cell killing
Speaker information
| Name | Position | Institution |
|---|---|---|
| Mark Krul | CEO | Inthera Bioscience |
Host and event manager:
Logistics and marketing partner:
